Search Results - drug+repurposing

4 Results

Sort By:

Drug Repurposing for Treatment of NGLY1 Deficiency

TECHNOLOGY SUMMARY A class of FDA approved drugs may be repurposed for use in treating NGLY1 deficiency. NGLY1 deficiency is a rare genetic disorder, caused by a lack of the enzyme N-glycanase, characterized by a variety of debilitating and isolating symptoms, including global developmental delay, movement disorders, seizures, ocular abnormalities,...

Published: 6/6/2019 | Inventor(s): Kuberan (kuby) Balagurunathan, Matthew Brendon Might, Yiling Bi

Keywords(s):

Category(s): Therapeutics, Drug Repurposing

BH4 (KUVAN) for Treatment of Systemic Sclerosis Vasculopathy

Invention SummarySystemic Sclerosis (SSc) SSc is a multisystem autoimmune disorder with a progressively devastating course. There is increased fibroblast activity resulting in abnormal growth of connective tissue causing vascular damage and fibrosis. Fibrosis occurs in skin, the gastrointestinal (GI) tract and other internal organs ;leading to digital...

Published: 9/13/2019 | Inventor(s): Anthony Donato, Tracy Frech

Keywords(s): Drug Repurposing, Therapeutics

Category(s): Therapeutics, Drug Repurposing

Method for Treating Suicidal Ideation and Behavior in Adolescent Populations With a Combination Therapeutic Including Creatine Analogs

Invention Summary: Creatine monohydrate (creatine) is a natural product that has been widely studied and used as a nutritional supplement designed to boost muscle performance in athletic competition. Investigators have recently begun to study creatine's mechanism-of-action in the brain and its potential efficacy in treating psychiatric disorders....

Published: 5/7/2019 | Inventor(s): Perry Renshaw, Douglas Kondo

Keywords(s):

Category(s): Therapeutics, Drug Repurposing

Methods for Treatment and Prevention of Acute Renal Failure and Multi-organ Failure

Invention Summary Acute Renal Failure (ARF), in the context of multi-organ failure and in high risk patients, remains a common, and often fatal (~50% mortality), complication. Preventative measures are only poorly effective, and dialysis therapy is expensive and time consuming. ARF is characterized by cell injury and death by necrosis and apoptosis...

Published: 7/17/2019 | Inventor(s): Christof Westenfelder

Keywords(s): Non-Cancer Disease Therapeutics

Category(s): Therapeutics, Drug Repurposing